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Abstract
Objective: The objective of  this study was to systematically appraise the quality of  an evidenced-based clinical algorithm for the 
clinical assessment of  hypotonia in children. 
Design: The Appraisal of  Guidelines for Research and Evaluation (AGREE) II tool with 23 items and six domains was used. 
The study was located in South Africa. Ten appraisers, who were recruited based on specific selection criteria, completed the 
assessment. 
Results: Nine appraisers recommended the EBCA without any modification. Scope and purpose (94%), stakeholder involve-
ment (91%) and editorial independence (99%) were rated the highest with the lower scoring domains being clarity of  presenta-
tion (85%) and applicability (86%) due to clarity required in areas of  resource implications and auditing and monitoring criteria. 
Inter-rater reliability was strong (ICC 0.7) amongst the appraisers in this study. 
Conclusion: This is the first independent assessment of  the methodological rigour and transparency of  a clinical algorithm 
using the AGREE-II instrument. Determining the quality of  the EBCA for practice is essential as this would ultimately aid cli-
nicians towards more accurate clinical assessment of  hypotonia which would inevitably impact outcomes and management of  
the child presenting with this symptom. Whilst the AGREE-II provided initial feedback on the methodological rigour of  devel-
opment, understanding that the AGREE-II instrument evaluates the guideline development process and not the content is also 
essential in order to consider the next stage which would be to consider clinicians feedback on the clinical utility of  this EBCA.
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Introduction
In recent years, the clinical assessment of  hypotonia has 
re-emerged as contentious, given the wide range of  diag-
noses that have hypotonia as an underlying symptom 1,2,3. 
The initial clinical evaluation is essential in the diagnostic 
process that ensues and in determining appropriate man-
agement4. In an attempt to address this contention ex-
pressed in the scientific literature, the author engaged in 
a systematic process towards the development of  an evi-
denced-based clinical algorithm (EBCA)5. This process is 
however incomplete without an appraisal of  the quality 
of  this process of  development.
 
Care pathways, algorithms and practice guidelines in clin-
ical research have developed as useful methods in stan-
dardising and guiding patient care6,7,8,9 and are promulgat-
ed to encourage high quality care10.  EBCA’s are tools that 
show promise as evidence is coded into specific rules and 
actions that facilitate delivery of  appropriate care to the 
relevant recipients of  the care9. However, although these 
EBCA’s and guidelines have a significant role in health-
care practice, their development process and their basis 
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of  evidence has been subject to criticism11. Given that 
these processes and tools have the potential to influence 
the healthcare of  many individuals, the method of  their 
development and assessment should be open to scruti-
ny11.
 
In order to assess the quality of  the developed EBCA 
5, the AGREE Collaboration’s Appraisal of  Guidelines 
for Research and Evaluation, version two (AGREE-II) 
instrument was identified as suitable12. Quality of  guide-
lines as defined by the collaboration12 is viewed as, "the 
confidence that the potential biases of  guideline develop-
ment have been addressed adequately and that the rec-
ommendations are both internally and externally valid, 
and are feasible for practice”. The AGREE II is generic, 
with application to guidelines across the health care con-
tinuum including screening, diagnosis and interventions. 
The application however has never been reported on the 
assessment of  an evidenced-based algorithm.
The author acknowledges that only once gaps in the sci-
entific evidence and its delivery have been addressed, then 
only can the issues around implementation and barriers 
be identified and overcome 9 with the developed EBCA 
5. In an attempt, to determine this quality of  the EBCA 
that was developed for the clinical assessment of  hypo-
tonia, an evaluation process with the use of  the AGREE 
II instrument 12 was initiated, the findings of  which are 
described in this paper.
 
Methods
The AGREE-II Instrument12 was used to assess the qual-
ity of  the clinical algorithm with respect to the meth-
odological rigor in development. A sample of  clinicians 
working in the field of  paediatrics in disciplines of  occu-
pational therapy, physiotherapy and paediatrics in addi-
tion to policy-makers, and guideline developers working 
in these three fields were recruited for participation as 
appraisers. The study was located in South Africa. The 
AGREE-II developers recommend that a guideline be 
assessed by at least two appraisers and preferably four 
as this will increase the reliability of  the assessment12. In 
this study, however a larger sample of  ten participants 
were selected in order to increase the reliability of  the 
assessment.
 
Quality in the AGREE-II instrument12 is assessed across 
six domains, namely, scope and purpose, stakeholder in-
volvement, rigor of  development, clarity of  presentation, 
applicability, and editorial independence, comprising a to-
tal of  23 items and two overall assessments. Each item 
is rated on a 7-point scale, either from 1 (strongly dis-
agree) to 7 (strongly agree). Data from the AGREE-II is 
expressed as calculated percentage scores. Domain and 
overall rating scores are calculated by a sum of  the indi-
vidual item scores for each appraiser (obtained scores) 
minus the minimum possible score minimum possible 
score per item (1, strongly disagree) × n items × n ap-
praisers. The total is expressed as a percentage of  the 
maximum possible score maximum possible score per 
item (7, strongly agree) × n items × n appraisers minus 
the minimum possible score, according to the formula12:
 
Each appraiser received a pack of  documents that included 
(i) a demographic questionnaire, (ii) the evidenced-based 
clinical algorithm, (iii) a technical report that accompa-
nied the algorithm, (iv) a copy of  the AGREE-II Man-
ual, (v) a copy of  the AGREE-II Scoring Sheets and 
(vi) a quick reference guide (explaining the domains and 
cross referencing it with the AGREE-II item and the 
technical Guideline item). The appraisers were given a 
maximum of  three weeks to complete the appraisal pro-
cess independently. Appraisers did not communicate or 
confer with eachother during the appraisal process. To 
preserve confidentiality, a research assistant collated the 
scores which were uploaded onto the My AGREE Plus 
site (www.agreetrust.org) for electronic collation. Qual-
itative comments were transposed onto a transcription 
sheet for coding. Each of  the items and the two overall 
rating items were assessed for their applicability to the 
clinical algorithm. A score of  1 was given when relevant 
information was very poorly reported or not provided or 
thought to be not applicable. Scores from 2 to 6 were as-
signed when the reporting did not meet the full criteria or 
considerations for an item, with scores increasing as more 
criteria and considerations were met. A score of  7 was 
given when the quality of  reporting was exceptional and 
all criteria and considerations were met in full for an item. 
The overall assessment of  the guideline was also assessed 
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and appraisers were requested to state if  they would rec-
ommend the guideline, recommend it with modifications 
or not recommend it. Inter-rater reliability was calculated 
using an intraclass correlation coefficient (two way ran-
dom mixed model) with SPSS version 23™ (IBM Corp, 
Armonk, NY, USA). The ICC provides a scalar measure 
of  agreement or concordance between raters. The sin-
gle measure of  the ICC is an index for the reliability of  
the ratings for one, typical, single rater whilst the average 
measure is an index for the reliability of  different raters 
averaged together13,14. ICC can thus be interpreted as 
follows, 0-0.2 (poor agreement); 0.3-0.4 (fair agreement); 
0.5-0.6 (moderate agreement); 0.7-0.8 (strong agreement); 
and >0.8 (almost perfect agreement).
Results
Demographic data of  the sample of  appraisers in this 
study are presented in Figure 1. The age and experience 
of  the appraisers were varied with nine of  the ten holding 
a master’s degree. The majority of  appraisers positioned 
themselves as guideline developers and researchers, with 
experience in policy and guideline development ranging 
from less than five years to up to 11-15 years. Half  of  
the appraisers considered themselves novice developers/
appraisers whilst the other half  considered them as being 
between a novice and expert in guideline development 
or appraisal. Six participants worked in academic settings, 
one worked only in a clinical setting, with three working 
in both an academic and clinical settings.
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Figure 1: Demographics of Appraisers in this Study (n=10) 
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Of  the ten appraisers that completed the AGREE-II in-
strument assessment, nine of  them indicated that they 
would recommend the EBCA for use (without mod-
ification) with one appraiser indicating that they would 
recommend the EBCA following modifications. Overall 
assessment of  the EBCA revealed a score of  91%. The 
mean domain scores and ranges for all appraisers are re-
flected in Table 1 with domain percentage scores that are 
also graphically highlighted in Figure 2. 
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Table 1:   The AGREE-II domains against which the EBCA was assessed (mean scores, range 














1 Scope and purpose is concerned with 
the overall aim of the guideline, the 
specific health questions and the 
target populations 
3 (21) 20 (17, 21) 94% 
2 Stakeholder involvement focuses on 
the extent to which the guideline was 
developed by the appropriate 
stakeholders and represents the 
views of its intended users 
3 (21) 19 (15,21) 91% 
3 Rigour of development relates to the 
process used to gather and 
synthesise the evidence, as well as 
the methods to formulate the 
recommendations and update them 
8 (56) 51 (45,56) 89% 
4 Clarity of Presentation deals with the 
language, structure and format of the 
guideline 
3 (21) 18 (11,21) 85% 
5 Applicability pertains to the likely 
barriers and facilitators to 
implementation, strategies to improve 
uptake and resource implications of 
applying the guidelines 
4 (28) 22 (15,28) 86% 
6 Editorial independence is concerned 
with the formulation of 
recommendations not being unduly 
biased with competing interests 
2 (14) 14 (13,14) 99% 
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The mean scores for each of  the 23 items are reflected 
in Table 2.
Qualitative comments by appraisers indicated that there 
was the evidence of  systematic methods and a clearly de-
scribed Delphi process. There was also the open invita-
tion to adapt the EBCA as new evidence emerges. Some 
appraisers felt that an expert review has been done, but 
may change as new evidence emerges. Others indicat-
ed that barriers and strengths including facilitators were 
clear. Moreover, recommendations for review as new evi-
dence becomes available had been made with evidence of  
changes from the original prototype presented.
However, from an interrogation of  individual item scores 
(Table 2), and comments from the appraisers, there is the 
need for greater discussion on the options for manage-
ment (mean 5.6), resource implications (mean 4.8) and 
monitoring and auditing data (mean 4.3) which reflected 
mean scores lower than the other 20 items and standard 
deviations ranging from 1.9 to 2.9 on these seven scale 
items.
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Description of Domain Items 
Overall rating of each item 







The overall objective(s) of the guideline is (are) 
specifically described 
6.7 (0.48) 
The health question(s) covered by the guideline is 
(are) specifically described 
6.4 (0.97) 
The population (patients) to which the guideline is 





The guideline development group includes 
professionals from all professional groups 
6.6 (0.70) 
The views and preferences of the target population 
have been sought 
6.2 (1.14) 






Systematic Methods were used to search for 
evidence 
7.0 (0) 
The criteria for selecting the evidence are clearly 
described 
6.5 (0.85) 
The strengths/limitations of the body of evidence 
are clearly described 
6.2 (1.23) 
The methods for formulating the recommendations 
are clearly described 
5.9 (0.99) 
The health benefits and risks have been considered 
in formulating the recommendations 
6.0 (1.05) 
There is an explicit link between the 
recommendations and the supporting evidence 
6.6 (0.70) 
The guideline has been externally reviewed by 
experts prior to its publication 
6.4 (0.70) 




The recommendations are specific and 
unambiguous 
6.0 (0.94) 
The different options for management of the 
condition or health issue are clearly presented 
5.6 (1.90) 




The guideline describes facilitators and barriers to 
its application 
6.5 (0.71) 
The guideline provides advice and/or tools on how 
recommendations can be put into practice 
6.4 (0.84) 
The potential resource implications of applying the 
recommendations have been considered 
4.8 (2.02) 





The views of the funding body have not influences 
the content of the guideline 
6.9 (0.32) 





  Table 3 reports the ICC. The ICC gives a composite of  intra-observer and inter-observer variability 14 thus two 
coefficients with their respective 95% confidence interval 
are indicated. The ICC will be high when there is little 
variation between the scores given to each item by the 
appraisers. A strong agreement(0.714) was present across 
all appraisers in this study (mean average reflected in Ta-
ble 3)  









95% Confidence Interval F Test with True Value 0 
Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures .200
a .091 .381 3.493 22 198 .000 
Average 
Measures .714 .501 .860 3.493 22 198 .000 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition. The between-measure variance is excluded from the denominator 
variance. 
Comments on the overall EBCA and accompanying tech-
nical report included the following:
 “User friendly, although appears overwhelming initially, upon read-
ing is logical and provides good guidelines for both the inexperienced 
and experienced clinician.” (Appraiser 1)
“This is a very interesting and useful guideline that could be used 
for a number of  other evaluations. User friendly, but a lot to take 
in at the beginning but great once you get used to the process” (Ap-
praiser 2)
“The guideline is clear and ready for use however improvement may 
be needed on instructions to use the algorithms”. (Appraiser 3)
 “The tool will certainly add value to clinical practice” 
(Appraiser 5)
“This is an extremely well developed algorithm with a thorough ev-
idence-based explanation of  its development and evolution. The one 
page "flow diagram" is certainly user-friendly and ready for use”. 
(Appraiser 6)
“The researcher succintly guides the review describing and summis-
ing each domain. It is easy to apply the AGREE-II in assessing 
her algorithm. Due to the paucity in this field I believe there will be 
immense value in the implementation” (Appraiser 7)
“An easy to read, easy to follow, comprehensive guideline that has 
taken all key areas into consideration” (Appraiser 8)
Discussion
In this study, the AGREE-II instrument was used to 
evaluate the quality of  an evidenced-based clinical al-
gorithm (EBCA) for the assessment of  hypotonia. The 
overall ratings of  the appraisers in this study generally 
indicate a high quality guideline. Together with the do-
main scores, the qualitative comments provided by the 
appraisers serve to assist the author in ensuring that the 
EBCA and accompanying technical report is ready for 
use in the clinical setting. Amid the six domains evaluat-
ed, the rated strengths of  the EBCA appear to lie in all 
six domains with higher scores in domains of  scope and 
purpose, stakeholder involvement and editorial indepen-
dence. This thus reflects the transparency with which the 
guideline had been developed in addition to involvement 
of  relevant stakeholders and the delineation of  the scope 
and purpose. 
Given that the AGREE II Consortium 12 has not set 
minimum domain scores or patterns of  scores across 
domains to differentiate between high quality and poor 
quality guidelines, the scores of  the AGREE-II evalua-
tion require careful interpretation. Thus in order to best 
represent the findings of  this evaluation, the author in-
cluded item and domain mean scores and standard de-
viations in order to demonstrate where the strengths lay, 
as well as items that showed variability, in addition to 
calculating inter-rater reliability. Authors who have used 
the AGREE-II tool have reported findings using means, 
medians, standard deviations for domain and item scores 
and weighted kappa, ICC and cronbachs alpha as reli-
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ability measures15,16,17,18.  Brouwers et al19,20 in their stud-
ies recommend that the number of  appraisers required 
in reaching a level of  inter-rater reliability of  0.7 ranged 
from two to five appraisers across domains. In this study 
ten appraisers were sampled in order to increase the reli-
ability and validity of  the findings.
 
This is the first independent assessment of  the method-
ological rigour and transparency of  a clinical algorithm 
as opposed to a clinical practice guideline using the 
AGREE-II instrument. The majority of  appraisers have 
recommended the EBCA for clinical use, however there 
has been three items that are worth interrogating in or-
der to improve the overall applicability and stakeholder 
uptake of  the EBCA. Firstly, the technical report and al-
gorithm is intended mainly for assessment and includes 
outputs for referrals for management. The appraisers 
who scored the item for options of  management low-
er commented on the need for the assessment algorithm 
to include more detail on management. Given that the 
underlying condition may be across a spectrum of  diag-
nosis, specific management would not be possible within 
this particular EBCA. A secondary process following this 
initial assessment would be required in order to first es-
tablish the diagnosis and then further management plans. 
These issues raised by the appraisers however, highlights 
the need for the delineation and boundaries of  this EBCA 
to be made explicit in the technical report to avoid confu-
sion of  what is offered. Secondly, whilst the implications 
of  applying recommendations have been considered and 
has been previously reported5 there was variability in the 
appraisers evaluations of  this item although details were 
provided in the technical report. Surprisingly, there were 
no comments on this item by the appraisers. This may be 
partially due to some of  the appraisers being convinced 
that this has been addressed with others differing with no 
recommendations for improvement. The author will thus 
consider resource implications as a point of  discussion 
prior to stakeholder uptake given that there is variability 
as to whether this has been adequately addressed.  Lastly, 
monitoring and auditing criteria were excluded from the 
technical report, but some appraisersevaluated this as-
pect. Comments include the fact that the annexures and 
evidence tables were difficult to follow whilst others in-
dicated that the changes made were described explicitly, 
based on stakeholder feedback, as well as by the inclu-
sion of  criteria that characterises hypotonia in the EBCA. 
Notwithstanding these comments and score, the author 
identifies the need for the inclusion of  operational defi-
nitions of  how each of  the criteria should be measured 
(although this is part of  the basic training of  the pro-
fessionals used in this study) and inferred in the EBCA. 
This may aid in greater uptake of  the EBCA in everyday 
clinical practice. 
Conclusion
Users of  clinical algorithms, care pathways and clinical 
practice guidelines and associated documents need to be 
assured that they are evidence-based. The appraisals in 
this study suggest that the process of  guideline develop-
ment and quality of  reporting for an evidenced-based 
clinical algorithm are robust.  However, successful im-
plementation will have to be carefully considered. Whilst 
the AGREE-II provided initial feedback on the method-
ological rigour of  development, understanding that the 
AGREE-II instrument evaluates the guideline develop-
ment process and not the content is also essential in order 
to consider the next stage which would be to consider 
clinicians feedback on the clinical utility of  this EBCA. 
Together with evaluating clinical utility and applicability, 
the author may augment this evaluation process with the 
administration of  the AGREE II-GRS Instrument (5-
item)12 to assess how well the guideline is reported by the 
actual end-users of  this EBCA and technical report. This 
may be appropriate especially when time and resources 
are limited for busy clinicians.  The evaluation process 
reported in this paper can thus be seen as the first step 
towards determining areas of  strength and potential ar-
eas for improvement that will ultimately aid in revisions 
and adjustments for maximal clinical benefit. As part of  
the implementation and knowledge exchange responsibil-
ities, the EBCA is in the process of  publication5. Whilst 
this may be considered effective from a clinical perspec-
tive, it does not take into account factors that may affect 
the adoption of  the EBCA by the end-users, and as such 
these processes mapping the way forward may seek to 
address these challenges identified.
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